Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin

A Combination of L-Arabinose and Chromium Lowers Circulating Glucose and Insulin Levels After Acute Oral Sucrose Challenge

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01107431

Acronym

L-Arabinose

Enrollment

Registered

2010-04-21

Start date

2008-12-31

Completion date

2009-12-31

Last updated

2011-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-diabetes

Keywords

glucose, insulin, L-arabinose, Chromium

Brief summary

This study was designed to examine changes in capillary blood glucose and venous insulin levels after a 70 gram oral sucrose challenge with and without simultaneous consumption of a dietary supplement containing L-Arabinose and a patented version of chromium (LA-Cr).

Detailed description

This study concluded that consumption of the LA-Cr supplement in conjunction with a 70-gram sucrose challenge led to a significant reduction of capillary blood glucose and venous insulin as compared to the sucrose challenge without the LA-Cr supplement. This finding may provide an important tool to reduce the adverse effects associated with elevated glucose and insulin levels.

Interventions

DIETARY_SUPPLEMENTL-Arabinose and Chromium

Consumed 70 grams of sucrose simultaneously taking a dietary supplement

DIETARY_SUPPLEMENTSucrose without dietary Supplement

Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* All study subjects were required to contact their family physician to ensure they had no medical conditions that would preclude their participation.

Exclusion criteria

* Diabetics, and * Those not approved by their physicians.

Design outcomes

Primary

Measure	Time frame	Description
Fasting Blood Glucose	Every 15 to 30 minutes	Finger-stick glucose measurements taken every 15 or 30 minutes after taking a 70 gram sucrose challenge with and without the dietary supplement

Secondary

Measure	Time frame	Description
Fasting Blood Insulin Levels	Every 30 minutes	A venipuncture blood test taken 30, 60, 90 and 120 minutes after taking a 70 gram sucrose challenge with and without taking the dietary supplement

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026